Cargando…
Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction
Osteosarcoma is an aggressive malignant bone tumor that causes bone destruction. Although tumor‐specific replicating oncolytic adenovirus OBP‐301 induces an antitumor effect in an osteosarcoma tumor, it cannot prevent bone destruction. Zoledronic acid (ZOL) is a clinically available agent that inhib...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581539/ https://www.ncbi.nlm.nih.gov/pubmed/28685948 http://dx.doi.org/10.1111/cas.13316 |
_version_ | 1783261070232649728 |
---|---|
author | Yamakawa, Yasuaki Tazawa, Hiroshi Hasei, Joe Osaki, Shuhei Omori, Toshinori Sugiu, Kazuhisa Komatsubara, Tadashi Uotani, Kouji Fujiwara, Tomohiro Yoshida, Aki Kunisada, Toshiyuki Urata, Yasuo Kagawa, Shunsuke Ozaki, Toshifumi Fujiwara, Toshiyoshi |
author_facet | Yamakawa, Yasuaki Tazawa, Hiroshi Hasei, Joe Osaki, Shuhei Omori, Toshinori Sugiu, Kazuhisa Komatsubara, Tadashi Uotani, Kouji Fujiwara, Tomohiro Yoshida, Aki Kunisada, Toshiyuki Urata, Yasuo Kagawa, Shunsuke Ozaki, Toshifumi Fujiwara, Toshiyoshi |
author_sort | Yamakawa, Yasuaki |
collection | PubMed |
description | Osteosarcoma is an aggressive malignant bone tumor that causes bone destruction. Although tumor‐specific replicating oncolytic adenovirus OBP‐301 induces an antitumor effect in an osteosarcoma tumor, it cannot prevent bone destruction. Zoledronic acid (ZOL) is a clinically available agent that inhibits bone destruction. In this study, we investigated the potential of combination therapy with OBP‐301 and ZOL against osteosarcomas with bone destruction. The antitumor activity of OBP‐301 and ZOL in monotherapy or combination therapy was assessed using three human osteosarcoma cell lines (143B, MNNG/HOS, SaOS‐2). The cytotoxic effect of OBP‐301 and/or ZOL was measured by assay of cell apoptosis. The effect of OBP‐301 and ZOL on osteoclast activation was investigated. The potential of combination therapy against tumor growth and bone destruction was analyzed using an orthotopic 143B osteosarcoma xenograft tumor model. OBP‐301 and ZOL decreased the viability of human osteosarcoma cells. Combination therapy with OBP‐301 and ZOL displayed a synergistic antitumor effect, in which OBP‐301 promoted apoptosis through suppression of anti‐apoptotic myeloid cell leukemia 1 (MCL1). Combination therapy significantly inhibited tumor‐mediated osteoclast activation, tumor growth and bone destruction compared to monotherapy. These results suggest that combination therapy of OBP‐301 and ZOL suppresses osteosarcoma progression via suppression of MCL1 and osteoclast activation. |
format | Online Article Text |
id | pubmed-5581539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-55815392017-09-06 Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction Yamakawa, Yasuaki Tazawa, Hiroshi Hasei, Joe Osaki, Shuhei Omori, Toshinori Sugiu, Kazuhisa Komatsubara, Tadashi Uotani, Kouji Fujiwara, Tomohiro Yoshida, Aki Kunisada, Toshiyuki Urata, Yasuo Kagawa, Shunsuke Ozaki, Toshifumi Fujiwara, Toshiyoshi Cancer Sci Original Articles Osteosarcoma is an aggressive malignant bone tumor that causes bone destruction. Although tumor‐specific replicating oncolytic adenovirus OBP‐301 induces an antitumor effect in an osteosarcoma tumor, it cannot prevent bone destruction. Zoledronic acid (ZOL) is a clinically available agent that inhibits bone destruction. In this study, we investigated the potential of combination therapy with OBP‐301 and ZOL against osteosarcomas with bone destruction. The antitumor activity of OBP‐301 and ZOL in monotherapy or combination therapy was assessed using three human osteosarcoma cell lines (143B, MNNG/HOS, SaOS‐2). The cytotoxic effect of OBP‐301 and/or ZOL was measured by assay of cell apoptosis. The effect of OBP‐301 and ZOL on osteoclast activation was investigated. The potential of combination therapy against tumor growth and bone destruction was analyzed using an orthotopic 143B osteosarcoma xenograft tumor model. OBP‐301 and ZOL decreased the viability of human osteosarcoma cells. Combination therapy with OBP‐301 and ZOL displayed a synergistic antitumor effect, in which OBP‐301 promoted apoptosis through suppression of anti‐apoptotic myeloid cell leukemia 1 (MCL1). Combination therapy significantly inhibited tumor‐mediated osteoclast activation, tumor growth and bone destruction compared to monotherapy. These results suggest that combination therapy of OBP‐301 and ZOL suppresses osteosarcoma progression via suppression of MCL1 and osteoclast activation. John Wiley and Sons Inc. 2017-08-03 2017-09 /pmc/articles/PMC5581539/ /pubmed/28685948 http://dx.doi.org/10.1111/cas.13316 Text en © 2017 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Yamakawa, Yasuaki Tazawa, Hiroshi Hasei, Joe Osaki, Shuhei Omori, Toshinori Sugiu, Kazuhisa Komatsubara, Tadashi Uotani, Kouji Fujiwara, Tomohiro Yoshida, Aki Kunisada, Toshiyuki Urata, Yasuo Kagawa, Shunsuke Ozaki, Toshifumi Fujiwara, Toshiyoshi Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction |
title | Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction |
title_full | Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction |
title_fullStr | Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction |
title_full_unstemmed | Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction |
title_short | Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction |
title_sort | role of zoledronic acid in oncolytic virotherapy: promotion of antitumor effect and prevention of bone destruction |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5581539/ https://www.ncbi.nlm.nih.gov/pubmed/28685948 http://dx.doi.org/10.1111/cas.13316 |
work_keys_str_mv | AT yamakawayasuaki roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT tazawahiroshi roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT haseijoe roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT osakishuhei roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT omoritoshinori roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT sugiukazuhisa roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT komatsubaratadashi roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT uotanikouji roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT fujiwaratomohiro roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT yoshidaaki roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT kunisadatoshiyuki roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT uratayasuo roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT kagawashunsuke roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT ozakitoshifumi roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction AT fujiwaratoshiyoshi roleofzoledronicacidinoncolyticvirotherapypromotionofantitumoreffectandpreventionofbonedestruction |